These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 10439927)

  • 1. The rationale and future potential of angiogenesis inhibitors in neoplasia.
    Gasparini G
    Drugs; 1999 Jul; 58(1):17-38. PubMed ID: 10439927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy.
    Ranieri G; Gasparini G
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Nov; 1(3):241-53. PubMed ID: 12477290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis: new targets for the development of anticancer chemotherapies.
    Gourley M; Williamson JS
    Curr Pharm Des; 2000 Mar; 6(4):417-39. PubMed ID: 10788590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of new drugs in angiogenesis.
    Ziche M; Donnini S; Morbidelli L
    Curr Drug Targets; 2004 Jul; 5(5):485-93. PubMed ID: 15216914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis.
    Drevs J; Schneider V
    J Intern Med; 2006 Dec; 260(6):517-29. PubMed ID: 17116002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
    Bahramsoltani M; Plendl J
    APMIS; 2007 Jan; 115(1):30-46. PubMed ID: 17223849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angiogenesis inhibitors in advanced cancer. Many current clinical trials show promising results].
    Christofferson R
    Lakartidningen; 1998 May; 95(20):2349-54. PubMed ID: 9630803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic alternatives to VEGF blockade.
    Khan KA; Bicknell R
    Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
    Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
    Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of angiogenesis.
    Folkman J; Ingber D
    Semin Cancer Biol; 1992 Apr; 3(2):89-96. PubMed ID: 1378314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options to target angiogenesis in human malignancies.
    Herbst RS
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):635-50. PubMed ID: 17064223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour angiogenesis.
    Le Querrec A; Duval D; Tobelem G
    Baillieres Clin Haematol; 1993 Sep; 6(3):711-30. PubMed ID: 7517738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.
    O'Byrne KJ; Steward WP
    Expert Opin Emerg Drugs; 2001 Apr; 6(1):155-74. PubMed ID: 15989502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
    van Kempen LC; Leenders WP
    Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.